Performance of 18fluorodeoxyglucose-positron emission tomography and somatostatin receptor scintigraphy for high Ki67 (≥10%) well-differentiated endocrine carcinoma staging

Journal of Clinical Endocrinology and Metabolism

Volumn 96, Issue 3, 2011, Pages 665-671

  Abgral, Ronan ^a   Leboulleux, Sophie ^b   Déandreis, Désirée ^b   Aupérin, Anne ^b   Lumbroso, Jean ^b   Dromain, Clarisse ^b   Duvillard, Pierre ^b   Elias, Dominique ^b   De Baere, Thierry ^b   Guigay, Joël ^b   Ducreux, Michel ^b   Schlumberger, Martin ^b   Baudin, Eric ^b  

^a BREST UNIVERSITY HOSPITAL   (France)

^b INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

[No Author keywords available]

Indexed keywords

5 HYDROXYINDOLEACETIC ACID; CHROMOGRANIN A; FLUORODEOXYGLUCOSE F 18; KI 67 ANTIGEN; PENTETREOTIDE IN 111;

ADULT; AGED; ARTICLE; CANCER MORTALITY; CANCER STAGING; CARCINOID SYNDROME; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CUSHING SYNDROME; DIAGNOSTIC TEST ACCURACY STUDY; DISTANT METASTASIS; ENDOCRINE TUMOR; FEMALE; HINDGUT TUMOR; HORMONE RELEASE; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPOGLYCEMIA; IMAGE ANALYSIS; INSULINOMA; INTERMETHOD COMPARISON; LUNG TUMOR; MAJOR CLINICAL STUDY; MALE; METASTASIS POTENTIAL; OVARY TUMOR; PANCREAS TUMOR; PATHOPHYSIOLOGY; PERFORMANCE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; SOMATOSTATIN RECEPTOR SCINTIGRAPHY; STOMACH TUMOR; SURVIVAL; THYMOMA; THYROID SCINTISCANNING; TREATMENT DURATION; TUMOR LOCALIZATION; WELL DIFFERENTIATED ENDOCRINE CARCINOMA;

AGED; CELL PROLIFERATION; ENDOCRINE GLAND NEOPLASMS; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; KI-67 ANTIGEN; MALE; MIDDLE AGED; NEOPLASM STAGING; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; RECEPTORS, SOMATOSTATIN; SOMATOSTATIN; SURVIVAL ANALYSIS; TOMOGRAPHY, X-RAY COMPUTED;

EID: 79952302230     PISSN: 0021972X     EISSN: 0021972X     Source Type: Journal    
DOI: 10.1210/jc.2010-2022     Document Type: Article

References (36)

1. Kwekkeboom DJ, Krenning EP, Scheidhauer K, Lewington V, Lebtahi R, Grossman A, Vitek P, Sundin A, Plöckinger U 2009 Mallorca Consensus Conference participants; European Neuroendocrine Tumor Society. ENETS consensus guidelines for the standards of care in neuroendocrine tumors: somatostatin receptor imaging with (111)In-pentetreotide. Neuroendocrinology 90:184-189
2. Baudin E 2007 Gastroenteropancreatic endocrine tumors: clinical characterization before therapy. Nat Clin Pract Endocrinol Metab 3:228-239
3. Faggiano A, Sabourin JC, Ducreux M, Lumbroso J, Duvillard P, Leboulleux S, Dromain C, Colao A, Schlumberger M, Baudin E 2007 Pulmonary and extrapulmonary poorly differentiated large cell neuroendocrine carcinomas: diagnostic and prognostic features. Cancer 110:265-274 (Pubitemid 47121885)
4. Volante M, Rosas R, Allìa E, Granata R, Baragli A, Muccioli G, Papotti M 2008 Somatostatin, cortistatin and their receptors in tumours. Mol Cell Endocrinol 286:219-229
5. Schillaci O 2007 Somatostatin receptor imaging in patients with neuroendocrine tumors: not only SPECT? J Nucl Med 48:498-500 (Pubitemid 47571402)
6. Jamar F, Fiasse R, Leners N, Pauwels S 1995 Somatostatin receptor imaging with indium-111-pentetreotide in gastroenteropancreatic neuroendocrine tumors: safety, efficacy and impact on patient management. J Nucl Med 36:542-549
7. Lebtahi R, Cadiot G, Sarda L, Daou D, Faraggi M, Petegnief Y, Mignon M, le Guludec D 1997 Clinical impact of somatostatin receptor scintigraphy in the management of patients with neuroendocrine gastroenteropancreatic tumors. J Nucl Med 38:853-858 (Pubitemid 27251972)
8. Krenning EP, Kwekkeboom DJ, Bakker WH, Breeman WA, Kooij PP, Oei HY, van Hagen M, Postema PT, de Jong M, Reubi JC 1993 Somatostatin receptor scintigraphy with [111In-DTPA-D-Phe1]- and [123I-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patients. Eur J Nucl Med 20:716-731 (Pubitemid 23284773)
9. Warburg O 1956 On respiratory impairment in cancer cells. Science 124:269-270
10. Higashi K, Ueda Y, Yagishita M, Arisaka Y, Sakurai A, Oguchi M, Seki H, Nambu Y, Tonami H, Yamamoto I 2000 FDG-PET measurement of the proliferative potential of non-small cell lung cancer. J Nucl Med 41:85-92 (Pubitemid 30046688)
11. Timmers HJ, Chen CC, Carrasquillo JA, Whatley M, Ling A, Havekes B, Eisenhofer G, Martiniova L, Adams KT, Pacak K 2009 Comparison of 18F-fluoro-L-DOPA, 18F-fluoro-deoxyglucose and 18F-fluorodopamine PET and 123I-MIBG scintigraphy in the localization of pheochromocytoma and paraganglioma. J Clin Endocrinol Metab 94:4757-4767
12. Pasquali C, Rubello D, Sperti C, Gasparoni P, Liessi G, Chierichetti F, Ferlin G, Pedrazzoli S 1998 Neuroendocrine tumor imaging: can 18F-fluorodeoxyglucose positron emission tomography detect tumors with poor prognosis and aggressive behavior? World J Surg 22:588-592
13. Belhocine T, Foidart J, Rigo P, Najjar F, Thiry A, Quatresooz P, Hustinx R 2002 Fluorodeoxyglucose positron emission tomography and somatostatin receptor scintigraphy for diagnosing and staging carcinoid tumours: correlations with the pathological indexes p53 and Ki-67. Nucl Med Commun 23:727-734 (Pubitemid 34837002)
14. Adams S, Baum R, Rink T, Schumm-Dräger PM, Usadel KH, Hör G 1998 Limited value of fluorine-18 fluorodeoxyglucose positron emission tomography for the imaging of neuroendocrine tumours. Eur J Nucl Med 25:79-83 (Pubitemid 28107907)
15. Erasmus JJ, McAdams HP, Patz Jr EF, Coleman RE, Ahuja V, Goodman PC 1998 Evaluation of pulmonary carcinoid tumors using FDG PET. AJR Am J Roentgenol 170:1369-1373 (Pubitemid 28210961)
16. Krüger S, Buck AK, Blumstein NM, Pauls S, Schelzig H, Kropf C, Schumann C, Mottaghy FM, Hombach V, Reske SN 2006 Use of integrated FDG PET/CT imaging in pulmonary carcinoid tumours. J Intern Med 260:545-550 (Pubitemid 44772374)
17. Garin E, Le Jeune F, Devillers A, Cuggia M, de Lajarte-Thirouard AS, Bouriel C, Boucher E, Raoul JL 2009 Predictive value of 18F-FDG PET and somatostatine receptor scintigraphy in patients with metastatic endocrine tumors. J Nucl Med 50:858-864
18. Rindi G, Azzoni C, La Rosa S, Klersy C, Paolotti D, Rappel S, Stolte M, Capella C, Bordi C, Solcia E 1999 ECL cell tumor and poorly differentiated endocrine carcinoma of the stomach: prognostic evaluation by pathological analysis. Gastroenterology 116:532-542 (Pubitemid 29106760)
19. Rindi G, Klöppel G, Alhman H, Caplin M, Couvelard A, de Herder WW, Erikssson B, Falchetti A, Falconi M, Komminoth P, Körner M, Lopes JM, McNicol AM, Nilsson O, Perren A, Scarpa A, Scoazec JY, Wiedenmann B; and all other Frascati Consensus Conference participants 2006 European Neuroendocrine Tumor Society (ENETS). TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading system. Virchows Arch 449:395-401
20. Rindi G, Klöppel G, Couvelard A, Komminoth P, Körner M, Lopes JM, McNicol AM, Nilsson O, Perren A, Scarpa A, Scoazec JY, Wiedenmann B 2007 TNM staging of midgut and hindgut (neuro) endocrine tumors: a consensus proposal including a grading system. Virchows Arch 451:757-762 (Pubitemid 47497934)
21. Solcia E, Klöppel G, Sobin LH 2000 Histological typing of endocrine tumors. World Health Organization International Histological Classification of Tumor. 2nd ed. Berlin, Heidelberg, New York: Springer
22. Pape UF, Jann H, Müller-Nordhorn J, Bockelbrink A, Berndt U, Willich SN, Koch M, Röcken C, Rindi G, Wiedenmann B 2008 Prognostic relevance of a novel TNM classification system for upper gastroenteropancreatic neuroendocrine tumors. Cancer 113:256-265
23. Bettini R, Boninsegna L, Mantovani W, Capelli P, Bassi C, Pederzoli P, Delle Fave GF, Panzuto F, Scarpa A, Falconi M 2008 Prognostic factors at diagnosis and value of WHO classification in a monoinstitution series of 180 non-functioning pancreatic endocrine tumours. Ann Oncol 19:903-908 (Pubitemid 351627305)
24. Hochwald SN, Zee S, Conlon KC, Colleoni R, Louie O, Brennan MF, Klimstra DS 2002 Prognostic factors in pancreatic endocrine neoplasms: an analysis of 136 cases with a proposal for low-grade and intermediate-grade groups. J Clin Oncol 20:2633-2642 (Pubitemid 34575635)
25. Ekeblad S, Skogseid B, Dunder K, Oberg K, Eriksson B 2008 Prognostic factors and survival in 324 patients with pancreatic endocrine tumor treated at a single institution. Clin Cancer Res 14:7798-7803
26. Durante C, Boukheris H, Dromain C, Duvillard P, Leboulleux S, Elias D, de Baere T, Malka D, Lumbroso J, Guigay J, Schlumberger M, Ducreux M, Baudin E 2009 Prognostic factors influencing survival from metastatic (stage IV) gastroenteropancreatic well-differentiated endocrine carcinoma. Endocr Relat Cancer 16:585-597
27. Yamamoto Y, Nishiyama Y, Ishikawa S, Nakano J, Chang SS, Bandoh S, Kanaji N, Haba R, Kushida Y, Ohkawa M 2007 Correlation of 18F-FLT and 18F-FDG uptake on PET with Ki-67 immunohistochemistry in non-small cell lung cancer. Eur J Nucl Med Mol Imaging 34:1610-1616 (Pubitemid 47476919)
28. Leboulleux S, Dromain C, Bonniaud G, Aupérin A, Caillou B, Lumbroso J, Sigal R, Baudin E, Schlumberger M 2006 Diagnostic and prognostic value of 18-fluorodeoxyglucose positron emission tomography in adrenocortical carcinoma: a prospective comparison with computed tomography. J Clin Endocrinol Metab 91:920-925 (Pubitemid 43357759)
29. Paulson EK, McDermott VG, Keogan MT, DeLong DM, Frederick MG, Nelson RC 1998 Carcinoid metastases to the liver: role of triple-phase helical CT. Radiology 206:143-150 (Pubitemid 28062998)
30. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG 2000 New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205-216
31. Kwekkeboom DJ, de Herder WW, Kam BL, van Eijck CH, van Essen M, Kooij PP, Feelders RA, van Aken MO, Krenning EP 2008 Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0,Tyr3]octreotate: toxicity, efficacy, and survival. J Clin Oncol 26:2124-2130
32. Cassier PA, Walter T, Eymard B, Ardisson P, Perol M, Paillet C, Chayvialle JA, Scoazec JY, Hervieu V, Bohas CL 2009 Gemcitabine and oxaliplatin combination chemotherapy for metastatic well-differentiated neuroendocrine carcinomas: a single-center experience. Cancer 115:3392-3399
33. Yu F, Venzon DJ, Serrano J, Goebel SU, Doppman JL, Gibril F, Jensen RT 1999 Prospective study of the clinical course, prognostic factors, causes of death, and survival in patients with long-standing Zollinger-Ellison syndrome. J Clin Oncol 17:615-630 (Pubitemid 29075250)
34. Clancy TE, Sengupta TP, Paulus J, Ahmed F, Duh MS, Kulke MH 2006 Alkaline phosphatase predicts survival in patients with metastatic neuroendocrine tumors. Dig Dis Sci 51:877-884 (Pubitemid 44030808)
35. Ahmed A, Turner G, King B, Jones L, Culliford D, McCance D, Ardill J, Johnston BT, Poston G, Rees M, Buxton-Thomas M, Caplin M, Ramage JK 2009 Midgut neuroendocrine tumours with liver metastases: results of the UKINETS study. Endocr Relat Cancer 16:885-894
36. Strosberg J, Nasir A, Coppola D, Wick M, Kvols L 2009 Correlation between grade and prognosis in metastatic gastroenteropancreatic neuroendocrine tumors. Hum Pathol 40:1262-1268